AwesomeCapital: 9 Policy Catalysts For Health Care Investors To Watch Before Year’s End

Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives. Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December in a recent note.

Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock RHHBY 0.11%, Sanofi SA SNY 0.47%, Takeda Pharmaceutical Co Ltd TKPYY 1.2%, Merck & Co., Inc. MRK 0.19%, Cardinal Health Inc CAH 0.45%, GlaxoSmithKline plc GSK 0.37%, Johnson & Johnson JNJ 0.23%, and Procter & Gamble Co PG 0.15%.

Two Imminent Measures

“We believe that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year,” Harris said.

Other key pieces of health care legislation might still make it through in 2019 as well, the analyst said.

“We further believe that legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix, and CREATES Act) are possible to enact in 2018, but Congress will more likely address these issues in 2019.”